Scarica l'app Stockscreener
19.90
0.66%
0.13
Dopo l'orario di chiusura:
19.70
-0.20
-1.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie
Big Picture: Will KalVista Pharmaceuticals Inc face regulatory challengesMarket Performance Recap & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Wall Street Zen Downgrades KalVista Pharmaceuticals (NASDAQ:KALV) to Hold - marketbeat.com
Why KalVista Pharmaceuticals (KALV) Is Up 5.0% After Promising Pediatric EKTERLY HAE Trial Results – And What's Next - Sahm
A Look At KalVista Pharmaceuticals (KALV) Valuation After Positive KONFIDENT KID EKTERLY Trial Update - Sahm
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 1-Year HighShould You Buy? - MarketBeat
KALV Should I Buy - intellectia.ai
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial - Yahoo Finance
KalVista Pharmaceuticals Stock: Positive Pediatric Trial Data Positions KALV for HAE Market Expansio - AD HOC NEWS
Hennion & Walsh Asset Management Inc. Boosts Stake in KalVista Pharmaceuticals, Inc. $KALV - marketbeat.com
KalVista reports interim data on pediatric HAE treatment trial By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference - BioSpace
(KALV) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
KalVista (KALV) Announces Positive Interim Results from KONFIDEN - GuruFocus
KalVista Announces Positive Interim Data for Pediatric HAE Treatment - National Today
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data - The National Law Review
KalVista reports interim data on pediatric HAE treatment trial - Investing.com
HC Wainwright Has Negative Forecast for KALV FY2028 Earnings - marketbeat.com
KalVista Pharmaceuticals Inc Stock Historical Valuations | HAM:4XC1 - GuruFocus
Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Sells 174,645 Shares of Stock - marketbeat.com
KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Sells 39,986 Shares of Stock - marketbeat.com
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded to Buy at Wall Street Zen - marketbeat.com
Venrock healthcare sells KalVista (KALV) shares for $3.69 million - Investing.com UK
Venrock healthcare sells KalVista (KALV) shares for $3.69 million By Investing.com - Investing.com South Africa
Venrock funds trim KalVista (KALV) stake, retain 5.09M shares - stocktitan.net
KalVista Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:KALV) - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS) - theglobeandmail.com
KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period - MSN
Wall Street analysts think KalVista Pharmaceuticals (KALV) could surge 117.1%: Read this before placing a bet - MSN
KalVista Pharmaceuticals (NASDAQ:KALV) Sets New 12-Month High Following Analyst Upgrade - marketbeat.com
KalVista Pharmaceuticals (KALV) Q4 Revenue Jump Tests Bullish Profitability Narrative - simplywall.st
H.C. Wainwright reiterates Kalvista stock Buy rating at $37 target By Investing.com - Investing.com Australia
Analysts Are Bullish on Top Healthcare Stocks: KalVista Pharmaceuticals (KALV), Achieve Life Sciences (ACHV) - theglobeandmail.com
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 8.7% on Analyst Upgrade - marketbeat.com
H.C. Wainwright reiterates Kalvista stock Buy rating at $37 target - Investing.com UK
KalVista Pharmaceuticals Inc Stock Baskets | HAM:4XC1 - gurufocus.com
Citizens cuts Kalvista Pharmaceuticals stock price target on steady launch By Investing.com - Investing.com Australia
KALV: Stifel Raises Price Target to $42 and Maintains Buy Rating - GuruFocus
KalVista Pharmaceuticals (NASDAQ:KALV) Given New $42.00 Price Target at Stifel Nicolaus - MarketBeat
Citizens Jmp Has Lowered Expectations for KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price - marketbeat.com
KalVista Pharmaceuticals (KALV) Target Price Lowered by Citizens Analyst | KALV Stock News - GuruFocus
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q1 2025 Earnings Call Transcript - insidermonkey.com
Needham & Company LLC Forecasts Strong Price Appreciation for KalVista Pharmaceuticals (NASDAQ:KALV) Stock - marketbeat.com
KalVista Pharmaceuticals, Inc. Q1 2025 Earnings Call Summary - Yahoo Finance
Citizens cuts Kalvista Pharmaceuticals stock price target on steady launch - Investing.com UK
KalVista Pharmaceuticals: Global Leader in Oral Therapies for Rare Diseases and HAE Treatment Expansion 42 - Minichart
Kalvista stock price target raised to $42 by Stifel on Ekterly demand - Investing.com Australia
KalVista reports $49.1M in EKTERLY sales for eight months By Investing.com - Investing.com India
Jefferies reiterates Kalvista stock rating on strong Ekterly sales By Investing.com - Investing.com Canada
Jefferies reiterates Kalvista stock rating on strong Ekterly sales - Investing.com UK
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):